A Phase 2b Open-label, Randomized Two-arm Study Comparing High and Low Doses of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Randomized two-arm, multicentre, open-label Phase 2b study of 2 doses of selinexor (KPT-330) in patients with relapsed/refractory de novo DLBCL who have no therapeutic options of
demonstrated clinical benefit.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society